All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

EMA Committee Recommends Piflufolastat 18F PSMA PET Imaging Agent for Prostate Cancer

June 1st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of piflufolastat 18F, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent, for use in prostate cancer detection.

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

June 1st 2023

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.

First Patient Dosed in EVEREST-1 Trial of A2B530 in Solid Tumors

June 1st 2023

The first patient has been dosed with the autologous CAR T-cell therapy A2B530 in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.

FCS Continues to Create Value Through Strategic Partnerships

June 1st 2023

Florida Cancer Specialists & Research Institute, LLC continues to forge new partnerships with alternative payment models and payers

Olverembatinib Recommended for Breakthrough Therapy Designation in China for SDH-Deficient GIST

June 1st 2023

The China National Medical Products Adminstration’s Center for Drug Evaluation has recommended that olverembatinib receive breakthrough therapy designation for the treatment of patients with gastrointestinal stromal tumor that is succinate dehydrogenase deficient.

New Trial Tests Chemotherapy Regimen Following Pancreatic Cancer Surgery

June 1st 2023

A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.

Subcutaneous Pertuzumab/Trastuzumab Combo Continues to Prove Safe, Effective in HER2+ Breast Cancer

June 1st 2023

Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer.

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

May 31st 2023

The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

May 31st 2023

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.

Panitumumab Plus Trifluridine-Tipiracil Improves Outcomes in RAS Wild-type mCRC

May 31st 2023

The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

May 31st 2023

Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.

Fox Chase Cancer Center’s Dr. Mary Daly Receives Inaugural Impact Award From Basser Center for BRCA

May 31st 2023

Fox Chase Cancer Center’s Mary Daly, MD, PhD, FACP was recently recognized as the first recipient of the BRCA Impact Award from Penn Medicine’s Basser Center for BRCA.

Epcoritamab Approval Introduces Novel Later-line Treatment Option in R/R DLBCL

May 31st 2023

Tycel Phillips, MD, discusses the significance of the FDA approval for epcoritamab in diffuse large B-cell lymphoma, key data from the EPCORE NHL-1 trial that support this approval, and how the approval of epcoritamab signals the expanding role of bispecific antibodies in this patient population.

Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma

May 31st 2023

Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.

PARP Inhibitors Represent Effective Upfront Ovarian Cancer Treatment Options

May 31st 2023

Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.

Acclaim-1 Trial of Quaratusugene Ozeplasmid Plus Osimertinib in NSCLC Advances Into Phase 2 Expansion

May 30th 2023

The safety review committee for the phase 1/2 Acclaim-1 trial has ruled that the study evaluating quaratusugene ozeplasmid in combination with osimertinib in patients with advanced non–small cell lung cancer can proceed to the phase 2 expansion portion.

Improvements in Personalized Medicine Allow for Greater Exploration of Treatment De-escalation in Breast Cancer

May 30th 2023

Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.

STAT2 Expression Is Higher in African American, Asian Patients With HCC

May 30th 2023

STAT2 expression in patients with hepatocellular carcinoma increases with tumor grade and cancer stage, with increases occurring at greater rates among Asian and African American patients.

Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting

May 30th 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

FDA Grants Priority Review to Lifileucel in Advanced Melanoma

May 30th 2023

The FDA has granted priority review to the biologics license application for the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.